Literature DB >> 33903674

Estimation of the timing of BAP1 mutation in uveal melanoma progression.

Ogul E Uner1,2, Thonnie Rose O See2, Eszter Szalai3, Hans E Grossniklaus4, Gustav Stålhammar5,6.   

Abstract

Uveal melanoma is the most common primary intraocular malignancy. A vast majority of metastasizing tumors have mutations in the BAP1 gene. Here, we investigate the spatiotemporal timing of these mutations. The size of 177 uveal melanomas and 8.3 million individual tumor cells was measured. BAP1 sequencing results and BAP1 IHC were available and for 76 (43%) and 101 (57%) of these, respectively. Tumors with a BAP1 mutation had significantly larger volume (2109 vs. 1552 mm3, p = 0.025). Similarly, tumor cells with loss of BAP1 protein expression had significantly larger volume (2657 vs. 1593 μm3, p = 0.027). Using observations of the time elapsed between mitoses, the BAP1 mutation was calculated to occur when the primary tumor had a size of a few malignant cells to 6 mm3, 0.5 to 4.6 years after tumor initiation and at least 9 years before diagnosis. We conclude that BAP1 mutations occur early in the growth of uveal melanoma, well before the average tumor is diagnosed. Its timing coincides with the seeding of micrometastases.

Entities:  

Year:  2021        PMID: 33903674     DOI: 10.1038/s41598-021-88390-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

1.  Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.

Authors:  Mrinali P Gupta; Anne Marie Lane; Margaret M DeAngelis; Katie Mayne; Margaux Crabtree; Evangelos S Gragoudas; Ivana K Kim
Journal:  JAMA Ophthalmol       Date:  2015-08       Impact factor: 7.389

2.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

3.  The Small Fatal Choroidal Melanoma Study. A Survey by the European Ophthalmic Oncology Group.

Authors:  Susanna Jouhi; Martine J Jager; Stefan J R de Geus; Laurence Desjardins; Nils Andreas Eide; Jean-Daniel Grange; Jens Folke Kiilgaard; Stefan Seregard; Edoardo Midena; Raffaele Parrozzani; Jean-Pierre Caujolle; Iwona Rospond-Kubiak; Tero T Kivelä
Journal:  Am J Ophthalmol       Date:  2019-02-15       Impact factor: 5.258

4.  Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.

Authors:  Carol L Shields; Minoru Furuta; Archana Thangappan; Saya Nagori; Arman Mashayekhi; David R Lally; Cecilia C Kelly; Danielle S Rudich; Anand V Nagori; Oojwala A Wakade; Sonul Mehta; Lauren Forte; Andrew Long; Elaina F Dellacava; Bonnie Kaplan; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2009-08

5.  Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

Authors:  Christina L Decatur; Erin Ong; Nisha Garg; Hima Anbunathan; Anne M Bowcock; Matthew G Field; J William Harbour
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

6.  Forty-year prognosis after plaque brachytherapy of uveal melanoma.

Authors:  Gustav Stålhammar
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 7.  Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.

Authors:  Babak Masoomian; Jerry A Shields; Carol L Shields
Journal:  J Curr Ophthalmol       Date:  2018-03-22

8.  Molecular profiling of driver events in metastatic uveal melanoma.

Authors:  Joakim Karlsson; Lisa M Nilsson; Suman Mitra; Samuel Alsén; Ganesh Vilas Shelke; Vasu R Sah; Elin M V Forsberg; Ulrika Stierner; Charlotta All-Eriksson; Berglind Einarsdottir; Henrik Jespersen; Lars Ny; Per Lindnér; Erik Larsson; Roger Olofsson Bagge; Jonas A Nilsson
Journal:  Nat Commun       Date:  2020-04-20       Impact factor: 14.919

9.  Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma.

Authors:  Christina Herrspiegel; Anders Kvanta; Emma Lardner; Louise Ramsköld Cabaca; Jill Wells; Katarina Bartuma; Stefan Seregard; Gustav Stålhammar
Journal:  Br J Ophthalmol       Date:  2020-06-10       Impact factor: 4.638

10.  Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013).

Authors:  Mary E Aronow; Allan K Topham; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-10-13
View more
  7 in total

Review 1.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

2.  No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.

Authors:  Shiva Sabazade; Christina Herrspiegel; Viktor Gill; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2021-11-24       Impact factor: 4.430

3.  Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.

Authors:  Shiva Sabazade; Viktor Gill; Christina Herrspiegel; Gustav Stålhammar
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-13       Impact factor: 4.553

Review 4.  The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.

Authors:  Anna Hagström; Ruba Kal Omar; Pete A Williams; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

5.  Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.

Authors:  Viktor Gill; Christina Herrspiegel; Shiva Sabazade; Maria Fili; Louise Bergman; Bertil Damato; Stefan Seregard; Gustav Stålhammar
Journal:  Front Med (Lausanne)       Date:  2022-06-02

6.  FOXD1 Is a Transcription Factor Important for Uveal Melanocyte Development and Associated with High-Risk Uveal Melanoma.

Authors:  Quincy C C van den Bosch; Josephine Q N Nguyen; Tom Brands; Thierry P P van den Bosch; Robert M Verdijk; Dion Paridaens; Nicole C Naus; Annelies de Klein; Emine Kiliç; Erwin Brosens
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

Review 7.  Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review.

Authors:  Nikola Serman; Semir Vranic; Mislav Glibo; Ljiljana Serman; Zrinka Bukvic Mokos
Journal:  Bosn J Basic Med Sci       Date:  2022-09-16       Impact factor: 3.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.